Precigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business Updates
FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date ...
Barinthus Biotherapeutics: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1 ...